Outcomes and treatment of chronic methicillin-resistant Staphylococcus aureus differs by staphylococcal cassette chromosome mec (SCCmec) type in children with cystic fibrosis

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 3, 2015, Pages 225-231

  Heltshe, Sonya L ^a,b   Saiman, Lisa ^c,d   Popowitch, Elena B ^e   Miller, Melissa B ^e   Kloster, Margaret ^b   Thompson, Valeria ^b   Ferkol, Thomas W ^f   Hoover, Wynton C ^g   Schechter, Michael S ^h,i   Muhlebach, Marianne S ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c Department of Medicine   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g University of Alabama at Birmingham   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cystic fibrosis; Methicillin resistant Staphylococcus aureus; Panton Valentine leukocidin; Pulmonary exacerbation; PVL; SCCmec type

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; EXOTOXIN; LEUKOCIDIN; PANTON-VALENTINE LEUKOCIDIN;

ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; CHILD; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEC GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; OXYGEN SATURATION; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; ADOLESCENT; CHRONIC DISEASE; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; EXOTOXINS; FEMALE; HUMANS; LEUKOCIDINS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 85006215389     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu048     Document Type: Article

References (38)

1. Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 2009; 8:8.
2. CFF-Registry. Available at: http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf. Accessed 2 June 2014.
3. Ren CL, Morgan WJ, KonstanMW, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007; 42:513-8.
4. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386-92.
5. Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-21.
6. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182:627-32.
7. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:1323-36.
8. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40:4289-94.
9. Tenover FC, McAllister S, Fosheim G, et al. Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J Clin Microbiol 2008; 46:2837-41.
10. Maree CL, Daum RS, Boyle-Vavra S, et al. Communityassociated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 2007; 13:236-42.
11. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish communityassociated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471-82.
12. Knight GM, Budd EL, Whitney L, et al. Shift in dominant hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) clones over time. J Antimicrob Chemother 2012; 67:2514-22.
13. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric CF patients and their household contacts. Pediatr Infect Dis J 2009; 28:895-9.
14. Glikman D, Siegel JD, David MZ, et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. Chest 2008; 133:1381-7.
15. Goodrich JS, Sutton-Shields TN, Kerr A, et al. Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J Clin Microbiol 2009; 47:1231-3.
16. Chen SY, Liao CH, Wang JL, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype affects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis 2012; 55:1329-37.
17. Haque NZ, Arshad S, Peyrani P, et al. Analysis of pathogen and host factors related to clinical outcomes in patients with hospitalacquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2012; 50:1640-4.
18. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761-70.
19. Wehrhahn MC, Robinson JO, Pascoe EM, et al. Illness severity in community-onset invasive Staphylococcus aureus infection and the presence of virulence genes. J Infect Dis 2012; 205:1840-8.
20. Rosenstein BJ. What is a cystic fibrosis diagnosis? Clin Chest Med 1998; 19:423-41.
21. Miller M, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003; 41:4009-15.
22. Champion EA, Miller MB, Popowitch EB, et al. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis. Pediatr Pulmonol 2014; 49:230-7.
23. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:2155-61.
24. Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88.
25. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000; (314):1-27.
26. Flegal KM, Wei R, Ogden C. Weight-for-stature compared with body mass index-for-age growth charts for the United States from the Centers for Disease Control and Prevention. Am J Clin Nutr 2002; 75:761-6.
27. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-65.
28. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303:1707-15.
29. Elizur A, Orscheln RC, Ferkol TW, et al. Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007; 131: 1718-25.
30. Tseng MH, Wei BH, Lin WJ, et al. Fatal sepsis and necrotizing pneumonia in a child due to community-acquired methicillinresistant Staphylococcus aureus: case report and literature review. Scand J Infect Dis 2005; 37:504-7.
31. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospitalacquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-62.
32. Lessa FC, Mu Y, Ray SM, et al. Impact of USA300 methicillinresistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin Infect Dis 2012; 55:232-41.
33. Hill RL, Kearns AM, Nash J, et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010; 65:442-5.
34. Endimiani A, Blackford M, Dasenbrook EC, et al. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother 2011; 55:1684-92.
35. Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11.
36. Kahl BC, Duebbers A, Lubritz G, et al. Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. J Clin Microbiol 2003; 41:4424-7.
37. Maslow JN, Brecher S, Gunn J, et al. Variation and persistence of methicillin-resistant Staphylococcus aureus strains among individual patients over extended periods of time. Eur J Clin Microbiol Infect Dis 1995; 14:282-90.
38. Branger C, Gardye C, Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol 1996; 45: 294-301.